Suppr超能文献

色甘酸钠治疗哮喘疗效与安全性的双盲多中心分组对照研究。北美替乐定研究组

A double-blind multicenter group comparative study of the efficacy and safety of nedocromil sodium in the management of asthma. North American Tilade Study Group.

出版信息

Chest. 1990 Jun;97(6):1299-306. doi: 10.1378/chest.97.6.1299.

Abstract

To determine the efficacy of nedocromil sodium in adult asthma patients using bronchodilators alone to control their disease, a consecutive sample of 127 patients with long-term asthma was studied for 16 weeks. The patients were maintained on sustained release theophylline preparations (SRT) and inhaled and oral beta-adrenergic bronchodilators (beta 2). One hundred sixteen patients (90 percent) completed the study; one placebo-treated patient withdrew owing to throat irritation and wheezing. Nedocromil sodium provided an additional benefit to adult patients receiving SRT and inhaled beta 2-agonists. With the exception of night-time asthma, nedocromil sodium maintained this improvement for the final 12 weeks of the study despite a reduction in concomitant bronchodilator therapy.

摘要

为确定奈多罗米钠对仅使用支气管扩张剂控制病情的成年哮喘患者的疗效,对连续抽样的127例长期哮喘患者进行了为期16周的研究。患者维持使用缓释茶碱制剂(SRT)以及吸入和口服β-肾上腺素能支气管扩张剂(β2)。116例患者(90%)完成了研究;1例接受安慰剂治疗的患者因咽喉刺激和喘息而退出。奈多罗米钠为接受SRT和吸入β2-激动剂的成年患者带来了额外益处。除夜间哮喘外,在研究的最后12周,尽管同时使用的支气管扩张剂治疗有所减少,但奈多罗米钠仍维持了这种改善效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验